- Home
- TVTX vs DNLI Comparison
TVTX vs DNLI Comparison
Compare TVTX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVTX | DNLI |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TVTX | DNLI |
|---|---|---|
| Price | $27.68 | $17.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $37.21 | $31.58 |
| AVG Volume (30 Days) | ★ 3.2M | 1.4M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $435,826,000.00 | N/A |
| Revenue This Year | $120.02 | N/A |
| Revenue Next Year | $37.00 | $3,975.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 114.22 | N/A |
| 52 Week Low | $12.91 | $10.57 |
| 52 Week High | $42.13 | $24.35 |
Technical Indicators
Market Signals| Indicator | TVTX | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 50.83 |
| Support Level | $22.59 | $17.88 |
| Resistance Level | $29.31 | $19.16 |
| Average True Range (ATR) | 2.44 | 0.86 |
| MACD | -1.18 | 0.14 |
| Stochastic Oscillator | 28.11 | 57.85 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.